Published in Gene Therapy Weekly, April 5th, 2001
The IND application was based on positive pre-clinical toxicology results for GTI-2501, an antisense compound, which demonstrated that the drug was well tolerated in studies using animals. The findings also suggested that GTI-2501 could be used safely in clinical trials with human patients, at concentration levels that exceed potential therapeutic doses.
"The FDA approval of our IND application allows Lorus to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.